GrayMatters Health, a digital therapeutics start-up company, announced that the BIRD Israel-U.S. Binational Industrial Research and Development Foundation awarded a grant to McLean Hospital and the company to develop a novel solution for the therapy of major depressive disorder (MDD) with anhedonia symptoms.
Based on GrayMatters’ patented fMRI-to-EEG machine learning platform, Prism, the treatment will enable individuals with MDD who do not have the ability to feel pleasure—also known as anhedonia—to learn how to control and regulate their reward system.
The McLean team will be led by Diego A. Pizzagalli, PhD, director of the Center for Depression, Anxiety, and Stress Research, and Kerry J. Ressler, MD, PhD, chief scientific officer, chief of the Division of Depression and Anxiety Disorders, co-director of the SPARED Conte Center, and director of the Neurobiology of Fear Laboratory.
“We are excited about this collaboration with GrayMatters Health and we are grateful to the BIRD Foundation for their support that will allow McLean and GrayMatters Health to advance our work together to develop innovative approaches to effectively treat depression,” said Scott L. Rauch, MD, McLean president and psychiatrist in chief.
Journalist or member of the media?
We are available 24/7 for media requests.